Evidence map›Paper›PMID 39612241›Full record

SynthesisAIDS (London, England)2025

Assessing coronavirus disease 2019 pandemic impacts on the health of people who inject drugs using a novel data sharing model.

Heather Bradley, Nicole Luisi, Anastasia Carter, Terri D Pigott, Daniela Abramovitz, Sean T Allen, Alice Asher, Chelsea Austin, Tyler S Bartholomew, Marianna Baum and 34 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Heather BradleyEmory University Rollins School of Public Health, Department of Epidemiology.
Nicole LuisiEmory University Rollins School of Public Health, Department of Epidemiology.
Anastasia CarterEmory University Rollins School of Public Health, Department of Epidemiology.
Terri D PigottGeorgia State University School of Public Health, Department of Population Health Sciences, Atlanta, GA.
Daniela AbramovitzUniversity of California San Diego School of Medicine, Division of Infectious Diseases and Global Public Health, La Jolla, CA.
Sean T AllenJohns Hopkins Bloomberg School of Public Health, Department of Health, Behavior, and Society, Baltimore, MD.
Alice AsherCenters for Disease Control and Prevention, Atlanta, GA.
Chelsea AustinGeorgia State University School of Public Health, Department of Population Health Sciences, Atlanta, GA.
Tyler S BartholomewUniversity of Miami Miller School of Medicine, Department of Public Health Sciences.
Marianna BaumFlorida International University R. Stempel College of Public Health and Social Work, Department of Dietetics and Nutrition, Miami, FL.
Amy BoardCenters for Disease Control and Prevention, Atlanta, GA.
Basmattee BoodramUniversity of Illinois Chicago School of Public Health, Division of Community Health Sciences, Chicago, IL.
Annick BorquezUniversity of California San Diego School of Medicine, Division of Infectious Diseases and Global Public Health, La Jolla, CA.
Kathryn A BrookmeyerCenters for Disease Control and Prevention, Atlanta, GA.
Kate BuchaczCenters for Disease Control and Prevention, Atlanta, GA.
Janet BurnettCenters for Disease Control and Prevention, Atlanta, GA.
Hannah L F CooperEmory University Rollins School of Public Health, Department of Epidemiology.
Nicole CrepazCenters for Disease Control and Prevention, Atlanta, GA.
Kora DebeckSimon Fraser University, School of Public Policy, Vancouver, B.C. Canada.
Judith FeinbergWest Virginia University Health Sciences, Morgantown, WV.
Chunki FongCity University of New York School of Public Health and Health Policy, Department of Community Health and Social Sciences, New York, NY.
Edward FreemanUniversity of Kentucky College of Public Health, Department of Epidemiology, Lexington, KY.
Nathan Woo FurukawaCenters for Disease Control and Prevention, Atlanta, GA.
Becky GenbergJohns Hopkins Bloomberg School of Public Health, Department of Health, Behavior, and Society, Baltimore, MD.
Pamina GorbachUniversity of California Los Angeles Fielding School of Public Health, Department of Epidemiology, Los Angeles, CA.
Holly HaganNew York University School of Global Public Health, New York, NY.
Kanna HayashiSimon Fraser University, Health Sciences, Burnaby, B.C., Canada.
Emalie HuriauxWashington State Department of Health, Turnwater, WA.
Hermione HurleyUniversity of Colorado School of Medicine, Division of Infectious Diseases, Aurora, CO.
Jeanne KerulyJohns Hopkins University School of Medicine, Division of Infectious Diseases.
Kathleen KristensenUniversity of Illinois Chicago School of Public Health, Division of Community Health Sciences, Chicago, IL.
Shenghan LaiUniversity of Maryland School of Medicine, Department of Epidemiology and Public Health, Baltimore, MD.
Natasha K MartinUniversity of California San Diego School of Medicine, Division of Infectious Diseases and Global Public Health, La Jolla, CA.
Pedro Mateu-GelabertCity University of New York School of Public Health and Health Policy, Department of Community Health and Social Sciences, New York, NY.
Gregory M McclainUniversity of Wisconsin School of Medicine and Public Health, Division of Infectious Disease, Madison, WI, USA.
Shruti MehtaJohns Hopkins Bloomberg School of Public Health, Department of Health, Behavior, and Society, Baltimore, MD.
Wing Yin MokBritish Columbia Centre on Substance Use, Vancouver, BC, Cananda.
Marley ReynosoNew York University School of Global Public Health, New York, NY.
Steffanie StrathdeeUniversity of California San Diego School of Medicine, Division of Infectious Diseases and Global Public Health, La Jolla, CA.
Nicole TorigianJohns Hopkins Bloomberg School of Public Health, Department of Health, Behavior, and Society, Baltimore, MD.
Chenziheng Allen WengNew York University School of Global Public Health, New York, NY.
Ryan WestergaardUniversity of Wisconsin School of Medicine and Public Health, Division of Infectious Disease, Madison, WI, USA.
April YoungUniversity of Kentucky College of Public Health, Department of Epidemiology, Lexington, KY.
Don C Des JarlaisNew York University School of Global Public Health, New York, NY.

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan · 1998 to 2026
$38.9M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
Risk Factors for HIV/AIDS in Drug UsersR01DA003574 · NIDA · NEW YORK UNIVERSITY · PI DES JARLAIS, DON C, MCKNIGHT, COURTNEY · 1986 to 2025
$16.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular DiseaseU01DA040325 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI LAI, SHENGHAN · 2016 to 2024
$12.7M
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDSU01DA038886 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI DEBECK, KORA, HAYASHI, KANNA · 2015 to 2024
$12.1M
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Marketsand Drug TourismR01DA049644 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2020 to 2024
$8.2M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
Increasing representation of black communities in SARS-CoV-2 serosurveys by understanding barriers and motivations for participationR01DA051302 · NIDA · GEORGIA STATE UNIVERSITY · PI BRADLEY, HEATHER, ROSENBERG, ELI SAMUEL · 2020 to 2024
$4.3M
NIAID NIH HHS P30 AI036214NIDA NIH HHS P30 DA011041NIDA NIH HHS R01 DA003574NIDA NIH HHS R01 DA041298NIDA NIH HHS R01 DA043484NIDA NIH HHS R01 DA049644NIDA NIH HHS R01 DA051302NIDA NIH HHS T32 DA037801NIDA NIH HHS U01 DA036297NIDA NIH HHS U01 DA036935NIDA NIH HHS U01 DA038886NIDA NIH HHS U01 DA040325NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG3 DA044826NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3 DA044826
6 · The paper itself

Abstract

objectiveUsing an innovative data sharing model, we assessed the impacts of the COVID-19 pandemic on the health of people who inject drugs (PWID).

designThe PWID Data Collaborative was established in 2021 to promote data sharing across PWID studies in North America. Contributing studies submitted aggregate data on 23 standardized indicators during four time periods: prepandemic (March 2019 to February 2020), early-pandemic (March 2020 to February 2021), mid-pandemic (March 2021 to February 2022), and late pandemic (March 2022 to February 2023).

methodsWe present study-specific and meta-analyzed estimates for the percentage of PWID who took medications for opioid use disorder, received substance use treatment, shared syringes or injection equipment, had a mental health condition, had been incarcerated, or had experienced houselessness. To examine change over time across indicators, we fit a random effects meta-regression model to prevalence estimates using time as a moderator.

resultsThirteen studies contributed estimates to the Data Collaborative on these indicators, representing 6213 PWID interviews. We observed minimal change across prevalence of the six indicators between the prepandemic (March 2019 to February 2020) and three subsequent time periods, overall or within individual studies. Considerable heterogeneity was observed across study-specific and time-specific estimates.

conclusionLimited pandemic-related change observed in indicators of PWID health is likely a result of policy and supportive service-related changes and may also reflect resilience among service providers and PWID themselves. The Data Collaborative is an unprecedented data sharing model with potential to greatly improve the quality and timeliness of data on the health of PWID.

Indexed as

COVID-19Information DisseminationSubstance Abuse, IntravenousHumansNorth AmericaOpioid-Related DisordersPandemicsSARS-CoV-2

Identifiers

PMID39612241
PMCPMC11872276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.